[ad_1]
The COVID-19 vaccine, developed by the US company Pfizer and the German company BioNtek, will be able to protect patients from infection for at least one year. This was stated by the CEO and co-founder of “BioNtek” Ugur Shahin.
All on the topic:
Coronavirus epidemic (COVID-19) 14905
“I hope the vaccine will be effective for at least a year,” he said, emphasizing that its re-administration could take place a year after the first vaccination.
According to him, the development of the preparation began at the end of January. In March, BioNtek announced its partnership with Pfizer. Shahin recalled that the vaccine has undergone clinical trials in both Germany and the United States.
This development is an important step in the fight against the pandemic at a time when there is a worldwide increase in new cases of infection, notes BTA.
On Monday, manufacturers released interim results of clinical trials, which show the vaccine is more than 90 percent effective.
All on the topic:
Coronavirus epidemic (COVID-19)
14905
More about the coronavirus
[ad_2]